HomeAI · summaries
Storia in 3 fonti
FDA approves Merck's oral PCSK9 drug, a first
Kalshi allows bets on clinical trial outcomes, Eli Lilly buys a psychedelic medicine, and more biotech news from The Readout
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Akero team, backed by Fairmount, launches new immunology company
FDA approves injectable Leqembi, another post-Makary reversal, and other biotech news from The Readout
- ·
forbes.com
Kalshi Is Letting People Bet On Clinical Trials And FDA Drug Decisions
Gamblers can now bet on how experimental drugs will perform in clinical trials—and if they’ll get FDA approval.
- ·
Kalshi comes for biopharma, with prediction markets for clinical trials and FDA approvals
Prediction markets have permeated the worlds of sports, politics, and reality television shows. Now, the biopharma industry could be next.
- ·
FDA approves Merck's oral PCSK9 drug, a first
Kalshi allows bets on clinical trial outcomes, Eli Lilly buys a psychedelic medicine, and more biotech news from The Readout
- ·
Pharmalittle: We're reading about Kalshi bets on clinical trials, a Merck cholesterol pill, and more
Kalshi, one of the world’s largest prediction market exchanges, plans to take bets on clinical trials and regulatory approvals
- ·
gizmodo.com
Kalshi Is Set to Start Taking Bets on Drug Trials
The landscape for potential market manipulation keeps expanding.